Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.04.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Zhen-Wei Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Marine Life Science, Ocean University of China, Qingdao 266003, PR China. Hauptthemen laut MEDLINE: Receptors, CXCR4, B7-H1 Antigen, Mice, Inbred C57BL. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Negative immunoregulatory signal (PD-L1, CXCR4, et al.) and weak immunogenicity elicited immune system failing to detect and destroy cancerous cells. CXCR4 blockade promoted T cell tumor infiltration and increased tumor sensitivity to anti-PD-L1 therapy. Here, pH-responsive reassembled nanomaterials were constructed with anti-PD-L1 peptide and CXCR4 antagonists grafting (APAB), synergized with photothermal therapy for melanoma and breast tumor interference. The self-assembled APAB nanoparticles accumulated in the tumor and rapidly transformed into nanofibers in response to the acidic tumor microenvironment, leading to the exposure of grafted therapeutic agents. APAB enabling to reassemble around tumor cells and remained stable for over 96 h due to the aggregation induced retention (AIR) effect, led to long-term efficiently combined PD-L1 and CXCR4 blockade. Photothermal efficiency (ICG) induced immunogenic cell death (ICD) of tumor cells so as to effectively improve the immunogenicity. The combined therapy (ICG@APAB) could effectively inhibit the growth of primary tumor (∼83.52%) and distant tumor (∼76.24%) in melanoma-bearing mice, and significantly (p < 0.05) prolong the survival time over 42 days. The inhibition assay on tumor metastasis in 4 T1 model mice exhibited ICG@APAB almostly suppressed the occurrence of lung metastases and the expression levels of CD31, MMP-9 and VEGF in tumor decreased by 82.26%, 90.45% and 41.54%, respectively. The in vivo reassembly strategy will offer novel perspectives benefical future immunotherapies and push development of combined therapeutics into clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Marine Life Science, Ocean University of China, Qingdao 266003, PR China.
- College of Marine Life Science, Ocean University of China, Qingdao 266003, PR China; Qingdao National Laboratory for Marine Science and Technology, Qingdao 266000, PR China.
- College of Marine Life Science, Ocean University of China, Qingdao 266003, PR China. Electronic address: yaliu@ouc.edu.cn.
Zitieren
APA
Deng, Z. W., Yang, J. K., Qiu, K. J., Zhang, T. J., He, Z., Wang, N., Chen, X. G., & Liu, Y. (2024). Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.04.048
Vancouver
Deng ZW, Yang JK, Qiu KJ, Zhang TJ, He Z, Wang N, et al. Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.04.048
BibTeX
@article{Deng2024,
author = {Deng, Zhen-Wei and Yang, Jian-Ke and Qiu, Kai-Jin and Zhang, Ting-Jie and He, Zheng and Wang, Na and Chen, Xi-Guang and Liu, Ya},
title = {Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.04.048}
}
EUVIMED